Summit Financial Wealth Advisors LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ – Get Rating) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,318 shares of the company's stock, valued at approximately $233,000.

A number of other institutional investors also recently bought and sold shares of the stock. Veracity Capital LLC grew its holdings in shares of Johnson & Johnson by 1.2% during the fourth quarter. Veracity Capital LLC now owns 5,027 shares of the company's stock worth $888,000 after buying an additional 59 shares in the last quarter. Sandy Cove Advisors LLC grew its stake in Johnson & Johnson by 1.6% during the 3rd quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company's stock valued at $605,000 after acquiring an additional 60 shares in the last quarter. Paces Ferry Wealth Advisors LLC raised its holdings in Johnson & Johnson by 0.7% in the 3rd quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company's stock valued at $1,425,000 after acquiring an additional 62 shares during the last quarter. Mason & Associates Inc boosted its holdings in shares of Johnson & Johnson by 4.9% during the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company's stock worth $215,000 after purchasing an additional 62 shares during the last quarter. Finally, Magnolia Capital Advisors LLC grew its position in shares of Johnson & Johnson by 0.7% in the third quarter. Magnolia Capital Advisors LLC now owns 8,883 shares of the company's stock valued at $1,451,000 after purchasing an additional 62 shares in the last quarter. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Up 1.0 %

Shares of NYSE JNJ opened at $152.65 on Friday. The stock has a fifty day simple moving average of $159.76 and a 200-day simple moving average of $167.55. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $186.69. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $397.54 billion, a PE ratio of 22.65, a PEG ratio of 2.60 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.22 by $0.13. The company had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. Johnson & Johnson's revenue was down 4.4% compared to the same quarter last year. During the same period in the previous year, the company posted $2.13 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.5 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were issued a dividend of $1.13 per share. The ex-dividend date was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.96%. Johnson & Johnson's dividend payout ratio (DPR) is presently 67.06%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on JNJ. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Guggenheim assumed coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They issued a "neutral" rating and a $161.00 price objective for the company. Piper Sandler reduced their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. SVB Leerink dropped their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an "outperform" rating for the company in a research note on Friday, January 20th. Finally, Atlantic Securities lifted their price target on shares of Johnson & Johnson from $160.00 to $168.00 and gave the company a "neutral" rating in a research report on Wednesday, January 25th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $174.73.

Insider Buying and Selling at Johnson & Johnson

In other news, insider James D. Swanson sold 1,062 shares of the stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.35% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women's Health and Wound Care markets.

See Also

• Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
• MarketBeat Week in Review – 3/20 – 3/24
• Dividend King Genuine Parts Company Upgraded On Profit Guidance
• The Bottom Is In For Accenture
• 11 Best Consumer Discretionary Stocks of 2023
• 10 Best Consumer Discretionary ETFs

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.